CN107213239A - A kind of Chinese medicine composition and its preparation method and application - Google Patents
A kind of Chinese medicine composition and its preparation method and application Download PDFInfo
- Publication number
- CN107213239A CN107213239A CN201710377149.5A CN201710377149A CN107213239A CN 107213239 A CN107213239 A CN 107213239A CN 201710377149 A CN201710377149 A CN 201710377149A CN 107213239 A CN107213239 A CN 107213239A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- weight
- parts
- medicine composition
- rhizoma atractylodis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Abstract
The invention provides a kind of Chinese medicine composition and preparation method thereof, the Chinese medicine composition is made up of the Chinese medicine material of following parts by weight：The parts by weight of golden cypress 9.5~12；The parts by weight of rhizoma atractylodis 3~6；The parts by weight of ginkgo leaf 4.5~6.The present invention also provides a kind of preparation method of Chinese medicine composition.In the Chinese medicine composition of the present invention, golden cypress is respectively provided with effect and the antiinflammatory action for preferably suppressing xanthine oxidase with ginkgo leaf, and rhizoma atractylodis have effect and the antiinflammatory action for preferably promoting uric acid excretion.Above-mentioned three medicines carry out compatibility can reduce the uric acid content in human body in terms of suppressing generation and promoting discharge two, and can effectively alleviate the inflammation of joint, therefore with the effect of preferably treatment acute gouty arthritis.
Description
Technical field
The invention belongs to technical field of traditional Chinese medicine, more particularly to a kind of Chinese medicine composition and preparation method thereof and should
With.
Background technology
Acute gouty arthritis is a kind of metabolic disorder class disease, its cardinal symptom for diseased joints it is red, swollen, hot,
Pain phenomenon.Acute gouty arthritis can also induce hypertension, atherosclerosis and lesions of liver and kidney etc. while breaking-out
Major disease, seriously endangers the health of the mankind.
The pathogenesis of acute gouty arthritis is that purine metabolic disturbance in patient's body increases so as to cause uric acid to gather
Many, excessive uric acid is deposited on joint, synovial membrane and surrounding tissue in the form of Monosodium urate is crystallized, and causes the inflammation at the position anti-
Should.It therefore, it can the activity of anti-inflammatory activity and suppression xanthine oxidase being used as and evaluate the anti-acute gout joint of medicine
The two indices of scorching activity.The medicine of commercially available treatment acute gouty arthritis mainly has non-steroid anti-inflammatory drug, xanthine
Oxidase inhibitor, uricosureic agent etc., but there is larger toxic side effect in these medicines.Therefore, from efficient, low toxicity,
The treatment preferable medicine of acute gouty arthritis effect is filtered out in the Chinese medicine of Mutiple Targets and the side of being grouped can reach preferably
Therapeutic purposes.
The content of the invention
In view of this, the invention aims to solve, the medicine poison of existing treatment acute gouty arthritis is secondary to be made
With the inapparent problem of big and effect, and provide a kind of Chinese medicine composition and its preparation method and application.
Present invention firstly provides a kind of Chinese medicine composition, it is made up of the Chinese medicine material of following parts by weight：
The parts by weight of golden cypress 9.5~12；
The parts by weight of rhizoma atractylodis 3~6；
The parts by weight of ginkgo leaf 4.5~6.
Preferably, described Chinese medicine composition, is made up of the Chinese medicine material of following parts by weight：
The parts by weight of golden cypress 10~11.5；
The parts by weight of rhizoma atractylodis 3.5~5.5；
The parts by weight of ginkgo leaf 4.5~5.5.
It is preferred that, described Chinese medicine composition is made up of the Chinese medicine material of following parts by weight：The parts by weight of golden cypress 10, rhizoma atractylodis 5
Parts by weight, the parts by weight of ginkgo leaf 5.
Present invention also offers a kind of preparation method of Chinese medicine composition, including：
A golden cypress) is added into ultrasonic extraction in alcohols solvent, cortex phellodendri extract is obtained；
B rhizoma atractylodis) are added into ultrasonic extraction in alcohols solvent, rhizoma atractylodis extract solution is obtained；
C ginkgo leaf) is added into ultrasonic extraction in alcohols solvent, ginkgo biloba succi is obtained；
D) by A), B), C) in obtain cortex phellodendri extract, rhizoma atractylodis extract solution and ginkgo biloba p.e mixing, obtain Chinese medicine
Composition.
It is preferred that, the A), B), C) in golden cypress, rhizoma atractylodis and ginkgo leaf be both needed to crush after extracted.
It is preferred that, the A), B), C) in alcohols solvent be 65%~75% ethanol water.
It is preferred that, the A), B), C) in golden cypress, the volume of rhizoma atractylodis or ginkgo leaf and the volume ratio of alcohols solvent be
1：(8~10).
It is preferred that, the A), B), C) in, Extracting temperature be 25~50 DEG C, extraction time be 1~2h.
The present invention also provides application of the above-mentioned Chinese medicine composition in treatment acute gouty arthritis medicine is prepared.
The pharmacological action of the present invention is as follows：
Golden cypress is the dry bark of rutaceae wampee, and its is bitter in taste, cold, with heat-clearing and damp-drying drug, purging intense heat, except steaming, solution
Poison treats effect of sore.Its modern pharmacology is acted on, anti-inflammatory, antibacterial, suppression xanthine oxidase, antigout etc..
Rhizoma atractylodis are the dry rhizome of feverfew Atractylis chinensis, its nature and flavor acrid, bitter, warm, with eliminating dampness Jian spleens, expelling wind and clearing away cold,
Effect of improving eyesight.Also there is the effect of the modern pharmacologies such as antibacterial, anti-inflammatory, decorporation urine, antigout simultaneously.
The dried leaf of ginkgo leaf Ginkgoaceae plant Ginkgo biloba, its nature and flavor are dry, bitter, puckery, flat, with promoting blood circulation and removing blood stasis, remove obstruction in channels to relieve pain,
Astringe the lung and relieving asthma, change effect of turbid lipid-loweringing.Also there is anti-inflammatory simultaneously, suppress the modern pharmacologies such as xanthine oxidase activity.
Beneficial effects of the present invention
The present invention provides a kind of Chinese medicine composition and its preparation method and application, and the Chinese medicine composition is by following parts by weight
Chinese medicine material is made：The parts by weight of golden cypress 9.5~12；The parts by weight of rhizoma atractylodis 3~6；The parts by weight of ginkgo leaf 4.5~6.The present invention is by Huang
Cypress, rhizoma atractylodis and ginkgo leaf carry out prescription, and golden cypress has preferable anti-inflammatory with ginkgo leaf and suppresses the activity of xanthine oxidase, grey
Art has preferable anti-inflammatory and promotes the activity of uric acid excretion.Above-mentioned a few herbs are subjected to compatibility, interaction, with anti-
Scorching, suppression uric acid generation and the effect for promoting uric acid excretion, the effect for the treatment of acute gouty arthritis is reached from multiple angles,
With preferable effect, and composition, due to using traditional Chinese medicine ingredients, toxic side effect is small.
Brief description of the drawings
Fig. 1 is the mass spectrum total ion current of xanthine oxidation reaction product uric acid of the present invention and internal standard substance 5 FU 5 fluorouracil
Figure.
Embodiment
The technical scheme in the embodiment of the present invention will be clearly and completely described below, it is clear that described implementation
Example only a part of embodiment of the invention, rather than whole embodiments.Based on the embodiment in the present invention, this area is common
The every other embodiment that technical staff is obtained under the premise of creative work is not made, belongs to the model that the present invention is protected
Enclose.
Present invention firstly provides a kind of Chinese medicine composition, it is made up of the Chinese medicine material of following parts by weight：
The parts by weight of golden cypress 9.5~12；
The parts by weight of rhizoma atractylodis 3~6；
The parts by weight of ginkgo leaf 4.5~6.
Preferably, described Chinese medicine composition is made up of the Chinese medicine material of following parts by weight：
The parts by weight of golden cypress 10~11.5；
The parts by weight of rhizoma atractylodis 3.5~5.5；
The parts by weight of ginkgo leaf 4.5~5.5.
It is further preferred that described Chinese medicine composition is made up of the Chinese medicine material of following parts by weight：
The parts by weight of golden cypress 10；
The parts by weight of rhizoma atractylodis 5；
The parts by weight of ginkgo leaf 5.
Present invention also offers a kind of preparation method of Chinese medicine composition, including：
A golden cypress) is added into ultrasonic extraction in alcohols solvent, cortex phellodendri extract is obtained；
B rhizoma atractylodis) are added into ultrasonic extraction in alcohols solvent, rhizoma atractylodis extract solution is obtained；
C ginkgo leaf) is added into ultrasonic extraction in alcohols solvent, ginkgo biloba succi is obtained；
D) by A), B), C) in obtain cortex phellodendri extract, rhizoma atractylodis extract solution and ginkgo biloba p.e mixing, obtain Chinese medicine
Composition.
According to the present invention, described golden cypress, rhizoma atractylodis and ginkgo leaf is preferably first crushed, institute before excusing from death extraction is carried out
The A stated), B), C) in alcohols solvent as Extraction solvent, described alcohols solvent is alcohols well known to those skilled in the art
Solvent, it is preferably ethanol, more preferably 65%~75% ethanol to have no in special limitation, the present invention；The alcohols
The volume of solvent and the ratio of golden cypress, rhizoma atractylodis or ginkgo leaf volume are both preferably (8~10)：1；The Extracting temperature is preferably 25
~50 DEG C, the extraction time is preferably 1~2h.
According to the present invention, the present invention is not particularly limited to the source of raw material golden cypress, rhizoma atractylodis and ginkgo leaf, is commercially available
.
Present invention also offers application of the above-mentioned Chinese medicine composition in treatment acute gouty arthritis medicine is prepared.
In order to further illustrate the present invention, a kind of Chinese medicine composition and its system provided with reference to embodiments the present invention
Preparation Method is described in detail.
Reagent used is commercially available in following examples.
Embodiment 1
After the golden cypress of 10 parts by weight is crushed, 75% ethanol of 8 times of volumes is added, 25~50 DEG C, ultrasonic extraction 1 is small
When, obtain cortex phellodendri extract；
After the rhizoma atractylodis of 3.5 parts by weight are crushed, 75% ethanol of 8 times of volumes is added, 25~50 DEG C, ultrasonic extraction 1 is small
When, obtain rhizoma atractylodis extract solution；
After the ginkgo leaf of 5.5 parts by weight is crushed, 75% ethanol of 8 times of volumes, 25~50 DEG C, ultrasonic extraction 1 are added
Hour, obtain ginkgo biloba succi；
Above-mentioned cortex phellodendri extract, rhizoma atractylodis extract solution and ginkgo biloba succi are mixed, Chinese medicine composition is obtained.
Embodiment 2
After the golden cypress of 10 parts by weight is crushed, 75% ethanol of 10 times of volumes is added, 25~50 DEG C, ultrasonic extraction 2 is small
When, obtain cortex phellodendri extract；
After the rhizoma atractylodis of 5 parts by weight are crushed, 75% ethanol of 10 times of volumes is added, 25~50 DEG C, ultrasonic extraction 2 is small
When, obtain rhizoma atractylodis extract solution；
After the ginkgo leaf of 5 parts by weight is crushed, 75% ethanol of 10 times of volumes is added, 25~50 DEG C, ultrasonic extraction 2 is small
When, obtain ginkgo biloba succi；
Above-mentioned cortex phellodendri extract, rhizoma atractylodis extract solution and ginkgo biloba succi are mixed, Chinese medicine composition is obtained.
Embodiment 3
After the golden cypress of 11.5 parts by weight is crushed, 75% ethanol of 9 times of volumes, 25~50 DEG C, ultrasonic extraction 1.5 are added
Hour, obtain cortex phellodendri extract；
After the rhizoma atractylodis of 5.5 parts by weight are crushed, 75% ethanol of 9 times of volumes, 25~50 DEG C, ultrasonic extraction 1.5 are added
Hour, obtain rhizoma atractylodis extract solution；
After the ginkgo leaf of 4.5 parts by weight is crushed, 75% ethanol of 9 times of volumes, 25~50 DEG C, ultrasonic extraction are added
1.5 hours, obtain ginkgo biloba succi；
Above-mentioned cortex phellodendri extract, rhizoma atractylodis extract solution and ginkgo biloba succi are mixed, Chinese medicine composition is obtained.
Comparative example 1
After the golden cypress of 8 parts by weight is crushed, 75% ethanol of 8 times of volumes of addition, 25~50 DEG C, ultrasonic extraction 1 hour,
Obtain cortex phellodendri extract.
After the rhizoma atractylodis of 8 parts by weight are crushed, 75% ethanol of 8 times of volumes of addition, 25~50 DEG C, ultrasonic extraction 1 hour,
Obtain rhizoma atractylodis extract solution.
After the ginkgo leaf of 4 parts by weight is crushed, 75% ethanol of 8 times of volumes is added, 25~50 DEG C, ultrasonic extraction 1 is small
When, obtain ginkgo biloba succi.
Above-mentioned cortex phellodendri extract, rhizoma atractylodis extract solution and ginkgo biloba succi are mixed, Chinese medicine composition is obtained.
Comparative example 2
After the golden cypress of 6.7 parts by weight is crushed, 75% ethanol of 10 times of volumes is added, 25~50 DEG C, ultrasonic extraction 2 is small
When, obtain cortex phellodendri extract.
After the rhizoma atractylodis of 6.7 parts by weight are crushed, 75% ethanol of 10 times of volumes is added, 25~50 DEG C, ultrasonic extraction 2 is small
When, obtain rhizoma atractylodis extract solution.
After the ginkgo leaf of 6.7 parts by weight is crushed, 75% ethanol of 10 times of volumes, 25~50 DEG C, ultrasonic extraction 2 are added
Hour, obtain ginkgo biloba succi.
Above-mentioned cortex phellodendri extract, rhizoma atractylodis extract solution and ginkgo biloba succi are mixed, Chinese medicine composition is obtained.
Comparative example 3
After the golden cypress of 5 parts by weight is crushed, 75% ethanol of 9 times of volumes is added, 25~50 DEG C, ultrasonic extraction 1.5 is small
When, obtain cortex phellodendri extract.
After the rhizoma atractylodis of 10 parts by weight are crushed, 75% ethanol of 9 times of volumes is added, 25~50 DEG C, ultrasonic extraction 1.5 is small
When, obtain rhizoma atractylodis extract solution.
After the ginkgo leaf of 5 parts by weight is crushed, 75% ethanol of 9 times of volumes, 25~50 DEG C, ultrasonic extraction 1.5 are added
Hour, obtain ginkgo biloba succi.
Above-mentioned cortex phellodendri extract, rhizoma atractylodis extract solution and ginkgo biloba succi are mixed, Chinese medicine composition is obtained.
Tested below by anti-inflammatory and the external xanthine oxidase that suppresses tests the effect for further illustrating the present invention：
1 anti-inflammatory is tested
The HUVEC damages that this experiment crystallizes induction with Monosodium urate are damaged for models coupling MTT experiment with Drug inhibition HUVEC
The inhibiting rate of wound is index, and the anti-inflammatory activity to medicine is evaluated.
1.1 experiment materials and reagent
Golden cypress, rhizoma atractylodis, ginkgo leaf are purchased from the big pharmacy in Changchun City Jilin.HUVEC cell lines buy in.DMEM
(Thermo), penicillin, streptomysin, trypsase, dimethyl sulfoxide (DMSO) (DMSO), 3- (4,5-Dimethylthiazol-2-
Yl) -2,5-diphenyltetrazolium bromide (MTT) are purchased from Sigma Co., USA；Hyclone (Thermo).
96 porocyte culture plates (Greiner, Germany)；ELIASA (TECAN, Australia)；CO2gas incubator (MCO-175,
SANYO)；Optics inverted microscope (XDS-1B, Chongqing optical instrument factory).
The preparation method of 1.2MSU solution
10mg MSU crystallizations are weighed, autoclaving 1h adds 100 μ L DMSO, then adds DMEM to be settled to 10mL, ultrasound
To dissolving 1mg/mL MSU storing solutions are made, the used time is diluted to respective concentration with DMEM in 30min.
1.3HUVEC in vitro culture
HUVEC is neutralized, 3500r/min through 0.25% Trypsin Induced with the DMEM nutrient solutions containing 10% hyclone
Centrifuge after 10min, abandoning supernatant, plus the DMEM nutrient solutions containing 10% hyclone, move into Tissue Culture Flask, be put into 37
DEG C, cultivate to exponential phase in 5%CO2 incubators.
1.4HUVEC cytoactive detection
With 0.25% Trypsin Induced HUVEC, with the density in 8000/ hole, 100 μ L are inoculated into 96 orifice plates, culture
24h, discards nutrient solution.50 μ L MSU solution (blank group is with 50 μ L DMEM replacements) is added per hole, every group of setting 6 is parallel
Hole.When crude drug concentration is 0.2mg/ml, the safe concentration of the Chinese medicines such as golden cypress, rhizoma atractylodis, ginkgo leaf is reached.Therefore, added per hole
Decoction in 50 μ L embodiment 1,2,3,4, making its final concentration of crude drug concentration 0.2mg/mL, (blank group and model group are with 50 μ L
DMEM replacements).It is put into incubator and cultivates 24h, discard decoction, 100 μ L MSU solution is added per hole, is put into incubator training
4h is supported, solution in hole is discarded, 150 μ L DMSO is added, is put into ELIASA, at 37 DEG C of low speed concussion dissolvings 10min, 570nm
Absorbance is detected, statistical analysis is carried out.Cell survival rate is drawn as follows：
IC%=(test hole absorbance average/blank well absorbance average) × 100%
1.5 experimental result
The anti-inflammatory activity of the different ratio compound of table 1 and the golden cypress rhizoma atractylodis medicine pair and ginkgo leaf simple of identical crude drug concentration
(mean ± SD, n=6)
From table 1 it follows that three comparative examples are poor to the inhibitory action of HUVEC cellular damages caused by Monosodium urate,
I.e. antiinflammatory action is poor, and between the Chinese medicine of composition compound and in the absence of obvious synergy.By comparison, embodiment 1-3
Chinese medicine composition is respectively provided with preferable anti-inflammatory activity, and inhibiting rate apparently higher than with crude drug concentration identical golden cypress rhizoma atractylodis in compound
The inhibiting rate of medicine pair and ginkgo leaf simple plus and, it can be said that with these ratios composition prescription after, ginkgo leaf and golden cypress
Rhizoma atractylodis medicine is worth to generating synergy in terms of anti-inflammatory with certain research and development.
The 2 external xanthine oxidase activities that suppress are tested
Xanthine oxidase oxidation xanthine generation uric acid is that uric acid produces most important approach in human body, and this section will be added
Xanthine oxidase oxidation xanthine generates the amount of uric acid after medicine, is compared with the amount that is not added with generation uric acid during medicine,
Analysis detection is carried out to the inhibiting rate of xanthine oxidase to medicine.
2.1 experiment materials and reagent
Golden cypress, rhizoma atractylodis, ginkgo leaf are purchased from the big pharmacy in Changchun City Jilin.Xanthine oxidase and Tris are purchased from the U.S.
Sigma companies；5 FU 5 fluorouracil is purchased from the Aladdin companies of Chinese Shanghai.Acetonitrile, formic acid are chromatographically pure (U.S. Fisher
Company)；Experimental water is Milli-Q ultra-pure waters.The other medicines do not mentioned and reagent are Beijing chemical reagents corporation product.
2.2 laboratory apparatus and equipment
UPLC-Q-TOF/MS is that Waters Synapt G2 quadrupole rods time of-flight mass spectrometer is equipped with Acquity UPLC systems
Unite in (Waters, the U.S.)；Ultra performance liquid chromatography-three-level quadrupole mass spectrometer (Acquity-Xevo TQ, Waters Corp.,
Milford,MA,USA)；The fast refrigerated centrifuge of Centrifuge 5810R hypervelocity (Eppendorf, Germany).
The measure of 2.3 xanthine oxidase inhibiting rates
Final volume is 200 μ L, 20mU/mL xanthine oxidase, and 150M xanthine, 50mM Tris-HCl bufferings are molten
Liquid (pH 8.7), (and the concentration of golden cypress rhizoma atractylodis and ginkgo leaf is accounted in compound the Chinese medicine extract of 5mg/mL crude drug concentration with it
Crude drug concentration is identical), 5min is reacted at 37 degrees Celsius, with the ice acetonitrile terminating reaction of four times of amounts, adds final concentration of 4 μM/L's
5 FU 5 fluorouracil crosses 0.22 μm of filter membrane as internal standard, carries out ultra performance liquid chromatography-three-level quadrupole rod mass spectral analysis.
Liquid-phase condition：Waters Acquity UPLC BEH C18 chromatographic columns (4.6 × 150mm i.d., 5 μm；The U.S.)；
Mobile phase A is acetonitrile, and B is the aqueous solution containing 0.1% formic acid；Flow velocity：0.3mL/min；Column temperature：25℃；Gradient：0-4min,
10%A (90%B) -30%A (70%B)；4-7min, 30%A (70%B) -80%A (20%B)；7-9min, 80%A (20%
B) -100%A (0%B).
Mass Spectrometry Conditions：ESI ion guns, anion scan pattern, capillary voltage 3.0kV；350 DEG C of desolvation temperature；
Desolvention gas velocity 650L/h；Taper hole gas velocity 50L/h；120 DEG C of ion source temperature.Inhibiting rate (%) is calculated as follows：
I=(A1-A2)/A1 × 100%
In formula, I is inhibiting rate of the decoction to xanthine oxidase；A1 is plus in the reaction system of decoction uric acid is not relatively interior
Mark the peak area of thing；A2 is peak area of the uric acid with respect to internal standard compound in the reaction system for have decoction.Xanthine oxidation reaction product
The mass spectrum total ion current figure of uric acid and internal standard substance 5 FU 5 fluorouracil is as shown in Figure 1.
2.4 mass spectrometry methods optimize
The Mass Spectrometry Conditions of the uric acid of table 2 and internal standard compound 5 FU 5 fluorouracil
2.5 experimental result
The suppression of the different ratio compound of table 3 and the golden cypress rhizoma atractylodis medicine pair of identical crude drug concentration with ginkgo leaf to xanthine oxidase
Rate (mean ± SD, n=6) processed
From table 3 it is observed that each comparative example is compared with embodiment, suppress the active poor of xanthine oxidase, and group
Into between the unit medicine of compound and in the absence of synergy.And each embodiment has preferable suppression to xanthine oxidase activity
Effect, and compound inhibiting rate is apparently higher than the suppression with crude drug concentration identical golden cypress rhizoma atractylodis medicine pair and ginkgo leaf simple in compound
Rate processed plus and, it can be said that after with these ratios composition prescription, ginkgo leaf and golden cypress rhizoma atractylodis medicine are to suppressing xanthine oxidase
Synergy is generated in terms of changing enzymatic activity, is worth with certain research and development.
By above-described embodiment, the present invention it is fully effective reached goal of the invention.It is familiar with the personage of this skill
It should be understood that the present invention includes but is not limited to the content described in accompanying drawing, subordinate list and above-described embodiment.It is any without departing from the present invention
The modification of function and principle be intended to be included in the scope of claims.
Claims (9)
1. a kind of Chinese medicine composition, it is characterised in that be made up of the Chinese medicine material of following parts by weight：
The parts by weight of golden cypress 9.5~12；
The parts by weight of rhizoma atractylodis 3~6；
The parts by weight of ginkgo leaf 4.5~6.
2. a kind of Chinese medicine composition according to claim 1, it is characterised in that by the Chinese medicine material system of following parts by weight
Into：
The parts by weight of golden cypress 10~11.5；
The parts by weight of rhizoma atractylodis 3.5~5.5；
The parts by weight of ginkgo leaf 4.5~5.5.
3. a kind of Chinese medicine composition according to claim 1, it is characterised in that by the Chinese medicine material system of following parts by weight
Into：The parts by weight of golden cypress 10, the parts by weight of rhizoma atractylodis 5, the parts by weight of ginkgo leaf 5.
4. a kind of preparation method of Chinese medicine composition according to claim 1-3 any one, it is characterised in that including：
A golden cypress) is added into ultrasonic extraction in alcohols solvent, cortex phellodendri extract is obtained；
B rhizoma atractylodis) are added into ultrasonic extraction in alcohols solvent, rhizoma atractylodis extract solution is obtained；
C ginkgo leaf) is added into ultrasonic extraction in alcohols solvent, ginkgo biloba succi is obtained；
D) by A), B), C) in obtain cortex phellodendri extract, rhizoma atractylodis extract solution and ginkgo biloba p.e mixing, obtain Chinese traditional medicine composition
Thing.
5. a kind of preparation method of Chinese medicine composition according to claim 4, it is characterised in that the A), B), C) in
Golden cypress, rhizoma atractylodis and ginkgo leaf are both needed to be extracted after crushing.
6. a kind of preparation method of Chinese medicine composition according to claim 4, it is characterised in that the A), B), C) in
Alcohols solvent is 65%~75% ethanol water.
7. a kind of preparation method of Chinese medicine composition according to claim 4, it is characterised in that the A), B), C) in
The volume ratio of golden cypress, the volume of rhizoma atractylodis or ginkgo leaf and alcohols solvent is 1：(8~10).
8. a kind of preparation method of Chinese medicine composition according to claim 4, it is characterised in that the A), B), C) in,
Extracting temperature is 25~50 DEG C, and extraction time is 1~2h.
9. the Chinese medicine composition according to claim 1-3 any one is in treatment acute gouty arthritis medicine is prepared
Application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710377149.5A CN107213239B (en) | 2017-05-25 | 2017-05-25 | Traditional Chinese medicine composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710377149.5A CN107213239B (en) | 2017-05-25 | 2017-05-25 | Traditional Chinese medicine composition and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107213239A true CN107213239A (en) | 2017-09-29 |
| CN107213239B CN107213239B (en) | 2020-09-04 |
Family
ID=59944364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710377149.5A Active CN107213239B (en) | 2017-05-25 | 2017-05-25 | Traditional Chinese medicine composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107213239B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112022966A (en) * | 2020-10-10 | 2020-12-04 | 中国药科大学 | Traditional Chinese medicine composition for preventing, relieving and/or treating hyperuricemia |
| CN114886961A (en) * | 2022-06-07 | 2022-08-12 | 安徽科技学院 | Traditional Chinese medicine composition for treating/preventing avian gout and preparation method and application thereof |
-
2017
- 2017-05-25 CN CN201710377149.5A patent/CN107213239B/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112022966A (en) * | 2020-10-10 | 2020-12-04 | 中国药科大学 | Traditional Chinese medicine composition for preventing, relieving and/or treating hyperuricemia |
| CN114886961A (en) * | 2022-06-07 | 2022-08-12 | 安徽科技学院 | Traditional Chinese medicine composition for treating/preventing avian gout and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107213239B (en) | 2020-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102558265B (en) | Extract method of cordyceps militaris adenosine | |
| CN101422563B (en) | Traditional Chinese medicine composition for treating wean sphagitis and preparation method and quality control method thereof | |
| CN107870216A (en) | The spectrum effect of polygonum capitatum opposed polarity position bacteriostasis learns analysis method | |
| CN107213239A (en) | A kind of Chinese medicine composition and its preparation method and application | |
| CN102961394A (en) | Application of geniposide in preparation of medicine for treating fatty liver disease | |
| CN108926584A (en) | The antimicrobial purposes of chimonanthea extract | |
| US10407455B2 (en) | Phillygenin glucuronic acid derivative as well as preparation method and application thereof | |
| CN108164524B (en) | Fibrauretine, extraction method thereof, fibrauretine capsule and preparation method thereof | |
| CN102198189A (en) | Preparation method of low-caffeine tea extract | |
| CN104382968A (en) | Method for extracting common andrographis paniculata total lactone, pharmaceutical composition of andrographis paniculata total lactone and use of pharmaceutical composition | |
| CN107260858A (en) | A kind of Chinese medicine composition and its preparation method and application | |
| CN108635391A (en) | A kind of hempleaf groundsel herb phenolic acid components and the preparation method and application thereof | |
| CN105198844A (en) | Novel limonin compound as well as preparation method and medical application thereof | |
| CN101491575B (en) | Traditional Chinese medicine extract for treating atopic dermatitis and granules thereof | |
| CN103408528A (en) | Chroman compound, as well as preparation method and application thereof | |
| CN105193885A (en) | Incised notopterygium rhizome extract as well as preparation method and application thereof | |
| CN102119953A (en) | Application of euphorbia humifusa wild extract | |
| TW201036624A (en) | Aurones as selective PDE inhibitors and their use in neurological conditions and disorders | |
| CN103655648B (en) | The preparation method of little leaf boxwood active component and purposes | |
| CN103316120B (en) | The purposes of Clausena excavata Burm.f. or its extract | |
| CN104920517B (en) | A kind of Herba Andrographitis aqua for preventing and treating brown rot of fruits and preparation method thereof | |
| CN108997468A (en) | Dandelion alkane type triterpenoid and its preparation method and application | |
| CN105343052B (en) | The application of RADIX PEUCEDANI aglycon | |
| CN103908493A (en) | Preparation method and pharmaceutical application of nux vomica total alkaloids | |
| CN102755276A (en) | Dalbergia wood perfume |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |